Cargando…

Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma

Lung cancer is the most common type of cancer worldwide with a high mortality rate. The specific tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR) have made enormous strides in non-small-cell lung cancer (NSCLC) treatment. The novel systemic immune-inflammation index (SII), a par...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ju, Qing, Huang, Tingping, Zhang, Yong, Wu, Lei, Geng, Jing, Mu, Xiaoyan, Yan, Tao, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886494/ https://www.ncbi.nlm.nih.gov/pubmed/33578585 http://dx.doi.org/10.1097/MD.0000000000024640

Ejemplares similares

High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs
por: Deng, Chao, et al.
Publicado: (2019)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report
por: Jiang, Yiqian, et al.
Publicado: (2021)

High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments
por: Zhao, Xiayan, et al.
Publicado: (2020)

Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI: A case report
por: Chen, Hui Jun, et al.
Publicado: (2021)

Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
por: Zhou, Jinhua, et al.
Publicado: (2023)

Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review
por: Chen, Xiaoli, et al.
Publicado: (2023)

Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma: A case report and review of the literature
por: Liu, Lei, et al.
Publicado: (2020)

Prognosis-related autophagy genes in female lung adenocarcinoma
por: Liu, Zhongxiang, et al.
Publicado: (2022)

Long-term survival in a patient with advanced non-smoking lung adenocarcinoma and no EGFR mutation after comprehensive therapy with EGFR-TKI-based therapy: A case report
por: Zhang, Qianyu, et al.
Publicado: (2022)

NCAPD2 is a novel marker for the poor prognosis of lung adenocarcinoma and is associated with immune infiltration and tumor mutational burden
por: Li, Zihao, et al.
Publicado: (2023)

Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma
por: Wang, Yuli, et al.
Publicado: (2018)

Epidermal growth factor receptor-mutant pulmonary adenocarcinoma coexisting with tuberculosis: A case report
por: Liu, Ning, et al.
Publicado: (2021)

Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
por: Zhang, Ping, et al.
Publicado: (2018)

Lung adenocarcinoma with EGFR gene mutation metastatic to the uterine cervix: A case report
por: Wang, Yong, et al.
Publicado: (2020)

Breast metastasis from EGFR/ALK negative lung adenocarcinoma: A case report
por: Cao, Liyu, et al.
Publicado: (2020)

Preoperative Serum CA125 Levels Predict the Prognosis in Hyperbilirubinemia Patients With Resectable Pancreatic Ductal Adenocarcinoma
por: Chen, Tao, et al.
Publicado: (2015)

Clinical characteristics and establishment of a 2-year-OS predictive model of EGFR mutation-positive patients with pleural invasion of lung adenocarcinoma
por: Kong, Qing, et al.
Publicado: (2023)

Association between systemic immune-inflammation index (SII) and survival outcome in patients with primary glioblastoma
por: Yang, Chao, et al.
Publicado: (2023)

Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report
por: Xu, Tongpeng, et al.
Publicado: (2017)

Multiple bioinformatics analysis identifies IGFBP1 as associated with the prognosis of stomach adenocarcinoma
por: Luo, Xiao-Ye, et al.
Publicado: (2023)

Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma
por: Isaka, Tetsuya, et al.
Publicado: (2015)

Relationship between a 7-mRNA signature of the pancreatic adenocarcinoma microenvironment and patient prognosis (a STROBE-compliant article)
por: He, Qing-lin, et al.
Publicado: (2020)

Exploration of genes and tumor infiltrating lymphocytes in female lung adenocarcinoma microenvironment that predicted prognosis
por: Wang, Lijun, et al.
Publicado: (2021)

Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature
por: Guo, Qiang, et al.
Publicado: (2023)

Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series
por: Li, Shih-Hong, et al.
Publicado: (2015)

Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
por: Inagaki, Yuji, et al.
Publicado: (2020)

Poorer prognosis in patients with advanced gastric squamous cell carcinoma compared with adenocarcinoma of the stomach: Case report
por: Meng, Ying, et al.
Publicado: (2017)

High WFDC3 gene expression is associated with poor prognosis and reduced immune cells infiltration in pancreatic adenocarcinoma: A study using the TCGA database and bioinformatics analysis
por: Wu, Wei, et al.
Publicado: (2023)

ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma
por: Li, Shuang-Shuang, et al.
Publicado: (2020)

Systemic immune-inflammation index (SII) is a useful prognostic indicator for patients with squamous cell carcinoma of the esophagus
por: Feng, Ji-Feng, et al.
Publicado: (2017)

The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis
por: Lan, Bo, et al.
Publicado: (2021)

Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report
por: Bie, Yanan, et al.
Publicado: (2021)

A novel gene signature derived from the CXC subfamily of chemokine receptors predicts the prognosis and immune infiltration of patients with lung adenocarcinoma
por: Deng, Kun, et al.
Publicado: (2022)

Big data analysis identified a telomere-related signature predicting the prognosis and drug sensitivity in lung adenocarcinoma
por: Zhang, Weiyi
Publicado: (2023)

Potential impact of WTAP and YTHDF2 on tumor immunity in lung adenocarcinoma
por: Zhang, Xinyu, et al.
Publicado: (2022)

EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
por: Yuan, Jin-Qiu, et al.
Publicado: (2017)

Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report
por: Zhao, Nan, et al.
Publicado: (2022)

Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma: A case report
por: Nong, Jingying, et al.
Publicado: (2021)

Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma
por: Dai, Dongjun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0ak28301fsfs94rmmpr2d64qvr